These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

267 related items for PubMed ID: 18332267

  • 1. Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial.
    Roy D, Pratt CM, Torp-Pedersen C, Wyse DG, Toft E, Juul-Moller S, Nielsen T, Rasmussen SL, Stiell IG, Coutu B, Ip JH, Pritchett EL, Camm AJ, Atrial Arrhythmia Conversion Trial Investigators.
    Circulation; 2008 Mar 25; 117(12):1518-25. PubMed ID: 18332267
    [Abstract] [Full Text] [Related]

  • 2. Usefulness of vernakalant hydrochloride injection for rapid conversion of atrial fibrillation.
    Pratt CM, Roy D, Torp-Pedersen C, Wyse DG, Toft E, Juul-Moller S, Retyk E, Drenning DH, Atrial Arrhythmia Conversion Trial (ACT-III) Investigators.
    Am J Cardiol; 2010 Nov 01; 106(9):1277-83. PubMed ID: 21029824
    [Abstract] [Full Text] [Related]

  • 3. Safety and efficacy of vernakalant for the conversion of atrial fibrillation to sinus rhythm; a phase 3b randomized controlled trial.
    Beatch GN, Mangal B.
    BMC Cardiovasc Disord; 2016 May 28; 16():113. PubMed ID: 27233239
    [Abstract] [Full Text] [Related]

  • 4. Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: a randomized, double-blind, placebo-controlled trial.
    Kowey PR, Dorian P, Mitchell LB, Pratt CM, Roy D, Schwartz PJ, Sadowski J, Sobczyk D, Bochenek A, Toft E, Atrial Arrhythmia Conversion Trial Investigators.
    Circ Arrhythm Electrophysiol; 2009 Dec 28; 2(6):652-9. PubMed ID: 19948506
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Efficacy and Safety of Vernakalant for Cardioversion of Recent-onset Atrial Fibrillation in the Asia-Pacific Region: A Phase 3 Randomized Controlled Trial.
    Beatch GN, Bhirangi K, Juul-Moller S, Rustige J.
    J Cardiovasc Pharmacol; 2017 Feb 28; 69(2):86-92. PubMed ID: 27828791
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. A randomized, placebo-controlled study of vernakalant (oral) for the prevention of atrial fibrillation recurrence after cardioversion.
    Torp-Pedersen C, Raev DH, Dickinson G, Butterfield NN, Mangal B, Beatch GN.
    Circ Arrhythm Electrophysiol; 2011 Oct 28; 4(5):637-43. PubMed ID: 21841207
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation.
    Camm AJ, Capucci A, Hohnloser SH, Torp-Pedersen C, Van Gelder IC, Mangal B, Beatch G, AVRO Investigators.
    J Am Coll Cardiol; 2011 Jan 18; 57(3):313-21. PubMed ID: 21232669
    [Abstract] [Full Text] [Related]

  • 14. Vernakalant for Rapid Cardioversion of Recent-Onset Atrial Fibrillation: Results from the SPECTRUM Study.
    Lévy S, Hartikainen J, Ritz B, Juhlin T, Carbajosa-Dalmau J, Domanovits H.
    Cardiovasc Drugs Ther; 2021 Apr 18; 35(2):283-292. PubMed ID: 33206300
    [Abstract] [Full Text] [Related]

  • 15. Spotlight on intravenous vernakalant in recent-onset atrial fibrillation.
    Duggan ST, Scott LJ.
    Drugs Aging; 2011 Jun 01; 28(6):501-4. PubMed ID: 21639409
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Pharmacological cardioversion of atrial fibrillation with vernakalant: evidence in support of the ESC Guidelines.
    Savelieva I, Graydon R, Camm AJ.
    Europace; 2014 Feb 01; 16(2):162-73. PubMed ID: 24108230
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Vernakalant: A novel agent for the termination of atrial fibrillation.
    Finnin M.
    Am J Health Syst Pharm; 2010 Jul 15; 67(14):1157-64. PubMed ID: 20592320
    [Abstract] [Full Text] [Related]

  • 20. Vernakalant in the management of atrial fibrillation.
    Cheng JW.
    Ann Pharmacother; 2008 Apr 15; 42(4):533-42. PubMed ID: 18334607
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.